Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Operating Expenses (2019 - 2026)

Pliant Therapeutics has reported Operating Expenses over the past 8 years, most recently at $21.8 million for Q1 2026.

  • Quarterly Operating Expenses fell 63.06% to $21.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $119.2 million through Mar 2026, down 49.25% year-over-year, with the annual reading at $156.4 million for FY2025, 31.52% down from the prior year.
  • Operating Expenses was $21.8 million for Q1 2026 at Pliant Therapeutics, down from $23.6 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $62.0 million in Q3 2024 and troughed at $21.8 million in Q1 2026.
  • The 5-year median for Operating Expenses is $45.6 million (2025), against an average of $42.9 million.
  • Year-over-year, Operating Expenses surged 48.0% in 2022 and then crashed 63.06% in 2026.
  • A 5-year view of Operating Expenses shows it stood at $39.4 million in 2022, then rose by 19.49% to $47.0 million in 2023, then rose by 13.36% to $53.3 million in 2024, then tumbled by 55.78% to $23.6 million in 2025, then fell by 7.66% to $21.8 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Operating Expenses are $21.8 million (Q1 2026), $23.6 million (Q4 2025), and $28.3 million (Q3 2025).